SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is seeing intense community engagement, rallying around its "OG meme" status from the early 2000s and actively building on Solana by restoring original meme-making tools. Despite broader market conditions, the community remains overwhelmingly bullish, consistently encouraging accumulation during dips and eagerly anticipating a significant move fueled by persistent calls for exchange listings.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is highly active amid escalating U.S.-Israeli military actions targeting Iran, with market participants intensely focused on the potential for sustained Middle East conflict and its implications for global oil supply, especially regarding the critical Strait of Hormuz. Community chatter is divided between those anticipating a significant oil price spike and others expecting a "sell the news" reaction or diplomatic de-escalation.

Omada Health, Inc. engages in the provision of digital health services. It offers online diabetes and obesity prevention programs, health coaching, and integration of web, mobile, and smart devices. The company was founded by Andrew DiMichele, Adrian James, and Sean Duffy in 2011 and is headquartered in South San Francisco, CA.

Omada Health Inc.

Omada Health, Inc.

Omada Health is trending due to strong preliminary earnings and accelerating member growth, particularly within its GLP-1 companion program, which has prompted multiple analyst upgrades and a surge of bullish sentiment. However, community discussions also highlight concerns about its revenue concentration with Cigna and the path to sustained profitability in the competitive digital health sector.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Escalating Middle East tensions are driving Chevron's trend, fueling community speculation for higher oil prices, while the company's recent Q4 earnings beat, dividend hike, and expanded Venezuela license further solidify bullish sentiment around its growth prospects.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending following reports of the death of Iran's Supreme Leader after US-Israel strikes, driving extensive community debate on geopolitical stability, potential market impacts, and whether the conflict serves as a distraction from the Epstein files.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Mounting geopolitical tensions in the Middle East, fueled by concerns over potential military actions and disruptions to the Strait of Hormuz, are driving significant investor and community discussion around Exxon Mobil, with many anticipating a substantial surge in oil prices and rotational interest into the energy sector.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Arvinas Inc

Arvinas is trending after the FDA accepted its New Drug Application for vepdegestrant, which validates its PROTAC platform and sets a June 2026 PDUFA date. The community is actively discussing the company's substantial cash position and upcoming clinical catalysts, fueling perceptions of an undervalued asset ripe for potential strategic moves.

MasTec, Inc. engages in the provision of infrastructure construction services. It operates through the following segments: Communications, Oil and Gas, Clean Energy and Infrastructure, and Other. The Communications segment performs engineering, construction, maintenance, and customer fulfillment activities related to communications infrastructure, primarily for wireless and wireline/fiber communications, and install-to-the-home customers. The Oil and Gas segment offers services on oil and natural gas pipelines and processing facilities for the energy and utilities industries. The Clean Energy and Infrastructure segment serves energy, utility and other end-markets through the installation and construction of power generation facilities, including from clean energy and renewable sources such as wind, solar and biomass, as well as various types of heavy civil and industrial infrastructure. The Other segment consists of equity investors, other small business units that perform construction, and other services for a variety of international end-markets. The company was founded by Jorge Mas Canosa on July 26, 1968, and is headquartered in Coral Gables, FL.

Mastec Inc.

MasTec Inc. is generating buzz following robust Q4 earnings and record backlog growth, primarily driven by strong demand in clean energy and power delivery sectors. The community is actively discussing the company's pivotal role in the accelerating AI data center and broader infrastructure build-out, fueling bullish sentiment.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Escalating geopolitical tensions in the Middle East, highlighted by reports of an oil tanker strike and threats to the Strait of Hormuz, are driving significant options activity and community debate around GUSH, with many anticipating a substantial upward move in oil and gas prices due to its leveraged exposure.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF is gaining traction as increased market volatility leads to expectations for robust monthly dividend payouts, solidifying its appeal among investors seeking consistent income and defensive positioning in an uncertain economic climate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Micro-Cap Stuns Market with Billion-Dollar Pipeline Valuation

It&#8217;s not often that a micro-cap company with a market value of around $40 million announces a third-party valuation of its drug development pipeline at $1.7 billion, 45% of which it owns. But that&#8217;s exactly what was revealed in a press release this morning. As expected, the stock reacted swiftly and rallied on the news.As mentioned, shares of Oncotelic Therapeutics <a href="https://www.allpennystocks.com/stockquote/OTLC" target="_blank">(OTCQB: OTLC)</a> are surging on news that the company announced a major milestone after its joint venture partner, GMP Bio, completed an independent third-party valuation of its drug development pipeline. The assessment, performed by Frost &amp; Sullivan (Hong Kong), values the pipeline at roughly $1.7 billion, translating to an estimated $765 million potential value for Oncotelic based on its 45% ownership stake. The company noted that this figure is forward-looking and non-binding, and it does not reflect fair value under U.S. GAAP. To support upcoming financial disclosures, a separate ASC-compliant valuation is already underway. If that analysis indicates a materially higher carrying value, Oncotelic may adjust future financial statements to reflect its increased minority interest, potentially boosting total assets and shareholder equity, pending the outcome of the review and applicable accounting standards.The joint venture has made significant progress across its therapeutic programs, including moving OT-101 into a Phase 3 PDAC trial and multiple Phase 2 combination studies. Meanwhile, GMP Bio is actively expanding its Deciparticle&#8482; nanomedicine platform, with several candidates advancing toward clinical development. Its San Diego GMP-licensed manufacturing facility is now fully operational and ready to support upcoming trials. Looking ahead, the JV is exploring a possible IPO on the Hong Kong Stock Exchange targeted for late 2026. While market conditions and regulatory approval will ultimately dictate the timing, Oncotelic views the strong pipeline valuation as a key indicator of the strategic value behind the potential offering.&#8220;This represents one of the most significant milestones in Oncotelic&#8217;s history,&#8221; said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics. &#8220;The independent valuation recognizes the multi-year scientific and clinical progress achieved through our GMP Bio joint venture and affirms the long-term potential of OT-101 and our Deciparticle&#8482; nanomedicine platform.&#8221;Shares of OTLC are currently trading up 26.15% at $0.09524 in mid-morning trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4012/micro-cap-stuns-market-with-billion-dollar-pipeline-valuation'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

Oncotelic Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$0.0464
Prev Close	$0.0458
Open	$0.048
Dividend Yield	0.00%
50-Day Moving Average	$0.0711
Beta	-0.07
Avg. Volume	149,816.85
PE Ratio	-11.32

52-Week High	$0.11
52-Week Low	$0.015
Market Capitalization	$20.54M
EPS (Annual)	-$0.0112
Price to Book	2.25
Revenue Per Employee	$0.00

OTLC
Oncotelic Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest OTLC News

OTLCOncotelic Therapeutics Inc